Literature DB >> 21435588

Foxp3(+) regulatory T cells promote T helper 17 cell development in vivo through regulation of interleukin-2.

Yi Chen1, Christopher J Haines, Ilona Gutcher, Kristin Hochweller, Wendy M Blumenschein, Terrill McClanahan, Günter Hämmerling, Ming O Li, Daniel J Cua, Mandy J McGeachy.   

Abstract

T helper 17 (Th17) cell development is driven by cytokines including transforming growth factor-β (TGF-β), interleukin-6 (IL-6), IL-1, and IL-23. Regulatory T (Treg) cells can provide the TGF-β in vitro, but their role in vivo remains unclear, particularly because Treg cells inhibit inflammation in many models of Th17 cell-associated autoimmunity. We used mice expressing Diphtheria toxin receptor under control of the Foxp3 promoter to deplete Foxp3(+) Treg cells in adult mice during in vivo Th17 cell priming. Treg cell depletion resulted in a reduced frequency of antigen-specific IL-17 producers in draining lymph nodes and blood, correlating with reduced inflammatory skin responses. In contrast, Treg cells did not promote IL-17 secretion after initial activation stages. Treg cell production of TGF-β was not required for Th17 cell promotion, and neither was suppression of Th1 cell-associated cytokines. Rather, regulation of IL-2 availability and resultant signaling through CD25 by Treg cells was found to play an important role.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21435588     DOI: 10.1016/j.immuni.2011.02.011

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  76 in total

1.  Re-establishing immunological self-tolerance in autoimmune disease.

Authors:  Shimon Sakaguchi; Fiona Powrie; Richard M Ransohoff
Journal:  Nat Med       Date:  2012-01-06       Impact factor: 53.440

2.  Mechanistic target of rapamycin complex 1 expands Th17 and IL-4+ CD4-CD8- double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus.

Authors:  Hiroshi Kato; Andras Perl
Journal:  J Immunol       Date:  2014-03-28       Impact factor: 5.422

Review 3.  Th17 cells: interactions with predisposing factors in the immunopathogenesis of inflammatory bowel disease.

Authors:  Ali Raza; Wajeeha Yousaf; Ralph Giannella; Mohamed Tarek Shata
Journal:  Expert Rev Clin Immunol       Date:  2012-02       Impact factor: 4.473

4.  MicroRNA-21 promotes Th17 differentiation and mediates experimental autoimmune encephalomyelitis.

Authors:  Gopal Murugaiyan; Andre Pires da Cunha; Amrendra K Ajay; Nicole Joller; Lucien P Garo; Sowmiya Kumaradevan; Nir Yosef; Vishal S Vaidya; Howard L Weiner
Journal:  J Clin Invest       Date:  2015-02-02       Impact factor: 14.808

Review 5.  Genetics and pathogenesis of inflammatory bowel disease.

Authors:  Bernard Khor; Agnès Gardet; Ramnik J Xavier
Journal:  Nature       Date:  2011-06-15       Impact factor: 49.962

Review 6.  Th17 cells and Tregs: unlikely allies.

Authors:  Xin Chen; Joost J Oppenheim
Journal:  J Leukoc Biol       Date:  2014-02-21       Impact factor: 4.962

Review 7.  Treg cells, life history, and diversity.

Authors:  Christophe Benoist; Diane Mathis
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-09-01       Impact factor: 10.005

8.  TNFR2 is critical for the stabilization of the CD4+Foxp3+ regulatory T. cell phenotype in the inflammatory environment.

Authors:  Xin Chen; Xueqiang Wu; Qiong Zhou; O M Zack Howard; Mihai G Netea; Joost J Oppenheim
Journal:  J Immunol       Date:  2012-12-31       Impact factor: 5.422

9.  Interleukin-10 (IL-10) inhibits Borrelia burgdorferi-induced IL-17 production and attenuates IL-17-mediated Lyme arthritis.

Authors:  Emily S Hansen; Velinka Medić; Joseph Kuo; Thomas F Warner; Ronald F Schell; Dean T Nardelli
Journal:  Infect Immun       Date:  2013-09-16       Impact factor: 3.441

Review 10.  The role and regulation of human Th17 cells in tumor immunity.

Authors:  Jian Ye; Rob S Livergood; Guangyong Peng
Journal:  Am J Pathol       Date:  2012-11-14       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.